Figure 4: PKA protein expression and the effect a PKA antagonist on antidepressant response and BDNF/CREB gene expression in the hippocampus after a single Yueju/ketamine treatment.
From: PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine
(A) PKA protein expression 1 day after Yueju (YJ) and Ketamine (KET) treatment in KM and ICR mice. PKA protein significantly increased in KM mice (F(2,17) = 13.228, p < 0.001) but not in ICR mice (F(2,17) = 0.541, p = 0.593). n = 6/group. *p < 0.05, ***p < 0.001, compared to control. (B) The effect of saline (F(2,23) = 13.413, p < 0.001) or H-89 (F(2,23) = 24.307, p < 0.001) pretreatment on immobility time in the tail suspension test 1 day after Yueju and ketamine treatment in KM mice. n = 8/group. **p < 0.01, ***p < 0.001, compared to vehicle (VEH, saline); ###p < 0.001, compared to vehicle (H-89); &&&p < 0.001, compared to YJ. (C) The effect of saline (F(2,11) = 15.173, p < 0.01) or H-89 (F(2,11) = 9.746, p < 0.01) pretreatment on BDNF mRNA expression 1 day after Yueju and ketamine treatment in KM mice. n = 4/group. **p < 0.01, compared to vehicle (saline); ##p < 0.01, compared to vehicle (H-89); &&p < 0.01, compared to YJ. (D) The effect of saline (F(2,11) = 11.688, p < 0.01) or H-89 (F(2,11) = 0.033, p = 0.968) pretreatment on CREB mRNA expression 1 day after Yueju and ketamine treatment in KM mice. n = 4/group. **p < 0.01, compared to vehicle (saline); &&p < 0.01, compared to YJ. Data represent means ± SEM.
